# Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors

> **NCT05505877** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Gopherwood Biotech Co., Ltd.** · enrollment: 160 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** BR790+Tislelizumab

## Key facts

- **NCT ID:** NCT05505877
- **Lead sponsor:** Shanghai Gopherwood Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-10
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2022-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05505877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05505877, "Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05505877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*